Proactive Management with Twice-Weekly Topical Cal/BD Foam Prolongs Treatment Efficacy Versus Reactive Management in Patients with Plaque Psoriasis

Document Type

Conference Proceeding

Publication Date

10-27-2021

Publication Title

J Cutan Med Surg

Abstract

Introduction: The PSO-LONG study showed that long-term proactive management with calcipotriol 50 μg/g/betamethasone dipropionate 0.5 mg/g (Cal/BD) foam was superior versus reactive management in patients with plaque psoriasis. This sub-analysis of PSO-LONG assessed the efficacy of four weeks daily treatment with Cal/BD foam and compared the sustained efficacy of proactive versus reactive management for up to 52 weeks Methods, Results: Following the initial four-week open-label lead-in phase (Cal/BD foam once daily [QD]), patients entered a 52-week randomised, double-blind maintenance phase and 8-week follow-up period. At maintenance phase entry, patients were randomised to proactive (continued Cal/BD foam) or reactive (vehicle foam) treatment twice weekly. Rescue treatment of Cal/BD QD for four weeks was given to patients experiencing a relapse (PGA ≥2), in either treatment group. If PGA was <2 after 4 weeks, maintenance therapy resumed, otherwise the patient was withdrawn if PGA was ≥2. mPASI and PGA scores were evaluated up to 52 weeks. In the 4-week open-label lead-in phase, 80% of patients (n = 521) achieved treatment success with significant improvements in mPASI and PGA scores (both P < 0.0001). After 4 weeks of the maintenance phase, a clear separation in mean PGA scores was observed, which was maintained throughout the study. The area under the curve (AUC) distribution for mean PGA score was 15% lower for proactive versus reactive therapy throughout the maintenance phase (1.35 versus 1.59; P = 0.0001) and was 20% lower for mean mPASI score (2.27 versus 2.84; P = 0.0005). The number of symptom-free days defined as PGA 0/1, mPASI 90, mPASI 75 or mPASI ≤3, was significantly higher with proactive versus reactive therapy (all P < 0.001). Conclusions: Proactive management of adult psoriasis patients with twice-weekly Cal/BD foam for up to 52 weeks was associated with sustained and significantly lower mean mPASI/PGA scores, and significantly more days in remission versus reactive management. Learning Objective To report the efficacy of four weeks of daily Cal/BD foam in the open-label lead-in phase of the PSO-LONG study To assess the sustained efficacy of proactive versus reactive management during the 52-week double-blind maintenance phase To compare the number of days in sustained remission between proactive and reactive management strategies Takeaway Message The efficacy of four weeks of daily treatment with Cal/BD foam is sustained when patients are transitioned to a proactive twice weekly maintenance regimen for up to 52 weeks.

Volume

25

Issue

1 SUPPL

First Page

66S

Find It @ Sladen

Share

COinS